Completed PHASE1 INTERVENTIONAL 1-arm NCT01588769

A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients (ALECSAT-GBM)

A Phase I Study to Investigate Tolerability and Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-cells (ALECSAT) Administered to Patients With Glioblastoma Multiforme (GBM)

Sponsor: CytoVac A/S

Conditions Glioblastoma Multiforme

Interventions ALECSAT cell based immunotherapy

Updated 5 times since 2017 Last updated: Jun 3, 2016 Started: Aug 31, 2011 Primary completion: Nov 30, 2012 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01588769, this PHASE1 trial focuses on Glioblastoma Multiforme and remains completed. Sponsored by CytoVac A/S, it has been updated 5 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CytoVac A/S

Data source: CytoVac A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Copenhagen, Denmark